Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mangravite et al. reply

Abstract

Replying to D. F. Carr et al. Nature 513, 10.1038/nature13628 (2014); J. S. Floyd et al. Nature 513, 10.1038/nature13629 (2014)

Our study1 tested for associations of single-nucleotide polymorphisms (SNPs) at the GATM loci with statin-induced myopathy based on the finding that one of these SNPs (rs986699) was associated with statin-induced expression of GATM in a panel of human lymphoblastoid cell lines, and the fact that GATM encodes the enzyme responsible for synthesis of creatine, a major source of energy in skeletal muscle1. Significant associations with incidence of myopathy were found for rs9806699 in statin users from the Marshfield Clinic cohort. Furthermore, significant association was reported in both the Marshfield cohort and in the SEARCH clinical trial of simvastatin treatment for two SNPs in linkage disequilibrium with the index SNP (rs1719247 and rs1346268, r2 > 0.7) that were genotyped in each of these groups. We have extended our meta-analysis to include the study data reported in the accompanying Comments by Carr et al.2 and Floyd et al.3, two studies that individually failed to replicate this association.

Main

The original analysis was performed on data from patients who were not on fibrates in the Marshfield and SEARCH populations. This was done to mitigate the risk that a possible modest protective effect of the SNPs would be masked by the known pharmacokinetic confounding caused by concomitant use of fibrates or other drugs that promote myopathy by altering statin pharmacokinetics4. We have done the same for the results of Floyd et al. in the meta-analyses presented below, although it is notable that, based on clinical presentation and creatine kinase levels, the majority of the myopathy cases of Floyd et al. were considerably more severe than in the originally reported cohorts5. This analytical approach was not possible for the study of Carr et al., since data for this subgroup were not provided. In this regard we note that because pharmacokinetic effects are major determinants of statin toxicity, the confirmation by both Carr et al. and Floyd et al. of an association of myopathy with a functional variant of the transporter gene SLC01B1 is not representative of the power of their analyses to detect a SNP association with a modest pharmacodynamic effect.

A fixed-effects meta-analysis yielded the following P values: rs9806699 (Marshfield, Carr et al. and Floyd et al.), P = 0.085; rs1719247 (Marshfield, SEARCH and Floyd et al.), P = 0.0042; rs1346268 (Marshfield, SEARCH and Floyd et al.), P = 0.0035. Thus, the statistical significance of the initially reported association is weakened but not eliminated by the inclusion of the additional cohorts. Future efforts to replicate these findings should give consideration to heterogeneity of patient characteristics, matching of statin exposure in cases and controls, avoidance of concomitant drug use and other confounding factors, and the statistical power to detect an association of modest effect size. We agree with Carr et al. that the association should be assessed in more patients and hope that a larger meta-analysis will be performed. In addition, further studies will be required to determine a mechanistic basis for a contribution of GATM genetic variation to the risk of statin-related myopathy. This Reply is written by the subset of authors that designed and led these analyses.

References

  1. 1

    Mangravite, L. M. et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377–380 (2013)

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2

    Carr, D. F. et al. GATM gene variants and statin myopathy risk. Nature 513, http://dx.doi.org/10.1038/nature13628 (2014)

  3. 3

    Floyd, J. S. et al. GATM locus does not replicate in rhabdomyolysis study. Nature 513, http://dx.doi.org/10.1038/nature13629 (2014)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Graham, D. J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J. Am. Med. Assoc. 292, 2585–2590 (2004)

    CAS  Article  Google Scholar 

  5. 5

    Marciante, K. D. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21, 280–288 (2011)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Lara M. Mangravite.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mangravite, L., Engelhardt, B., Stephens, M. et al. Mangravite et al. reply. Nature 513, E3 (2014). https://doi.org/10.1038/nature13630

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing